20 Aug 2024
// PRESS RELEASE
01 Jul 2024
// PRESS RELEASE
03 Jun 2024
// PRESS RELEASE
Latest Content by PharmaCompass
Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.
About
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
Severity: Warning
Message: Undefined variable $tile1
Filename: tabs/exhibitions.php
Line Number: 43
Backtrace:
File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
Line: 43
Function: _error_handler
File: /var/www/html/application/models/CmnPec.php
Line: 1625
Function: view
File: /var/www/html/application/views/include/party/query.php
Line: 575
Function: create
File: /var/www/html/application/views/include/party/indexNew.php
Line: 70
Function: include
File: /var/www/html/application/views/commonNew.php
Line: 445
Function: include
File: /var/www/html/application/controllers/PharmaServices.php
Line: 4651
Function: view
File: /var/www/html/index.php
Line: 224
Function: require_once
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities
20 Aug 2024
// PRESS RELEASE
https://www.aurigeneservices.com/sites/default/files/2024-08/Media%20note-%20DRL-APSL%20partnership%20with%20Kainomyx.pdf
01 Jul 2024
// PRESS RELEASE
https://www.aurigeneservices.com/sites/default/files/2024-07/APSL%20Edity%20Media%20note.pdf
03 Jun 2024
// PRESS RELEASE
https://www.aurigeneservices.com/sites/default/files/2024-06/Genomevalley-facility-press%20release-final-3rd-June-2024.pdf
19 Apr 2024
// PRESS RELEASE
https://www.aurigeneservices.com/sites/default/files/2024-04/APSL%20Vipergen%20Partnership_Media%20Note.pdf
04 Apr 2024
// PRESS RELEASE
https://www.aurigeneservices.com/sites/default/files/2024-04/Aurigene-Pharma-Aurigene.AI_.pdf
03 Apr 2024
// BUSINESSWIRE
Details:
Kainomyx has agreed to lead the technical strategy and associated aspects for drug discovery and clinical phases, Aurigene has agreed to focus on developing cost-effective and scalable drug chemistry.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Kainomyx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Kainomyx
Deal Size : Undisclosed
Deal Type : Agreement
Dr. Reddy's, Aurigene, Kainomyx Partner For Affordable Anti-Malarial Drug
Details : Kainomyx has agreed to lead the technical strategy and associated aspects for drug discovery and clinical phases, Aurigene has agreed to focus on developing cost-effective and scalable drug chemistry.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
August 20, 2024
Details:
Fermenta Biotech will exclusively license its biocatalytic technology for synthesis of Molnupiravir (Molflu) and supply its enzyme Candida Antarctica B Lipase (CAL B) to Aurigene. Molnupiravir API manufactured by Aurigene will be utilised by Dr Reddy’s for its formulation.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Molflu
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Fermenta Biotech Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2022
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Fermenta Biotech Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Fermenta Biotech will exclusively license its biocatalytic technology for synthesis of Molnupiravir (Molflu) and supply its enzyme Candida Antarctica B Lipase (CAL B) to Aurigene. Molnupiravir API manufactured by Aurigene will be utilised by Dr Reddy’s...
Brand Name : Molflu
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 21, 2022
Details:
This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed.
Lead Product(s): PENAO,Sirolimus
Therapeutic Area: Oncology Brand Name: PENAO
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: PENAO Pty Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 18, 2021
Lead Product(s) : PENAO,Sirolimus
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : PENAO Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
Details : This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed.
Brand Name : PENAO
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2021
Details:
Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: The Global Antibiotic Research and Development Partnership
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Lead Product(s) : Zoliflodacin,Ceftriaxone,Azithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : The Global Antibiotic Research and Development Partnership
Deal Size : Undisclosed
Deal Type : Agreement
GARDP, Dr. Reddy’s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access T...
Details : Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 17, 2020
Services
API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Pharma Service : API Manufacturing
Drug Product Manufacturing
API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Aurigene Pharmaceutical Services
Category : API Development
Sub Category : High Potency APIs (HPAPIs)
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Aurigene Pharmaceutical Services
Category : API Development
Sub Category : Oligosaccharides & Polysaccharides
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Aurigene Pharmaceutical Services
Category : API Development
Sub Category : Oligonucleotide / Polynucleotide
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Aurigene Pharmaceutical Services
Category : Formulation Development
Sub Category : Inhalation / Nasal
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Aurigene Pharmaceutical Services
Category : Formulation Development
Sub Category : Pediatric Formulation
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Aurigene Pharmaceutical Services
Category : Formulation Development
Sub Category : Injectable / Parenteral
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Inspections and registrations
District Decision : Voluntary Action Indicated
Inspection End Date : 2016-06-15
Aurigene Pharmaceutical Services
City : Hyderabad
State :
Country/Area : India
Zip :
District :
Center :
Project Area : Drug Quality Assurance
District Decision : Voluntary Action Indicated
Inspection End Date : 2016-06-15
District Decision : No Action Indicated
Inspection End Date : 2019-03-21
Aurigene Pharmaceutical Services
City : Hyderabad
State :
Country/Area : India
Zip :
District :
Center :
Project Area : Bioresearch Monitoring
District Decision : No Action Indicated
Inspection End Date : 2019-03-21
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?